Taysha Gene Therapies, Inc. Overview
Pro stress-test →Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with its lead clinical program TSHA-102 in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The company is pursuing a critical regulatory pathway with significant momentum toward commercialization.
Strategic Profile
Pro stress-test →TSHA-102 has reached FDA written alignment on inclusion of safety data from the ASPIRE trial to support a broad label in patients aged 2 years and older with Rett syndrome, streamlining the path toward BLA submission. With dosing completion expected in Q2 2026 across pivotal trials and an estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., EU and U.K., Taysha is positioned to redefine the treatment paradigm for this devastating disease with high unmet need.
Competitive Landscape
Pro stress-test →Taysha operates in the AAV gene therapy space for CNS rare genetic diseases. Primary competitors include Regenxbio, Neurochlore, and other AAV-focused developers. Taysha's differentiation stems from breakthrough therapy designation, robust clinical efficacy data (100% response rate in Part A), and proven AAV9 platform with experienced management team in gene therapy development and commercialization.
Industry Context
Taysha Gene Therapies, Inc. operates in Biotechnology - Gene Therapy (CNS/Rare Genetic Diseases).
Key facts
Founded: 2019 · Headquarters: Dallas, Texas · Market cap: $1.2B